A Study of Apabetalone in Subjects With Long -COVID

This study is testing whether a drug called apabetalone, combined with a diabetes medication called dapagliflozin, can help reduce the ongoing symptoms of Long COVID in people who also have Type 2 diabetes. Long COVID includes persistent fatigue, brain fog, and other symptoms that continue for months after a COVID-19 infection. **You may be eligible if...** - You are 18 or older and have Type 2 diabetes - You are currently taking or willing to start taking dapagliflozin - You had Long COVID symptoms starting within 3 months of a COVID-19 infection, and those symptoms have lasted at least 2 months - Your Long COVID is significantly impacting your life (scored above 30 on the Long Covid Impact Tool) - You currently test negative for COVID-19 **You may NOT be eligible if...** - You have severe kidney disease (eGFR below 25) - You have severe heart failure (NYHA Class IV) - You have liver cirrhosis, active hepatitis, or significant liver abnormalities - You have HIV, Hepatitis B, or Hepatitis C - You received a COVID-19 vaccine or booster within the last 30 days - You are pregnant, planning pregnancy, or breastfeeding Talk to your doctor to see if this trial is right for you.